Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Download PDF

B cell-based therapy produces antibodies that inhibit glioblastoma growth

Link

Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies

Link

"*" indicates required fields

Phone

This field is for validation purposes and should be left unchanged.

Salutation*

First Name*

Last Name*

Email*

Country/Region*

Institution/Company*

Industry*

Position*

Research area*

Organ*

Stage of research*

Does your laboratory perform stainings on tissue samples?*

Consent*

I agree to receive relevant information and updates from Lunaphore about its products. You can unsubscribe from this list at any time. For further information please review the Privacy Policy and Legal Statement on our website.

CAPTCHA

Legal Privacy Cookie Policy Terms and Conditions Cookie Settings

Tolochenaz, Switzerland

[email protected]

+41 21 353 58 10

COMET™ is CE/UKCA/UL marked and is For Research Use Only.
Not for use in diagnostic procedures.

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Related Articles

B cell-based therapy produces antibodies that inhibit glioblastoma growth

Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies